A Phase 1 Open-Label Study to Assess the Effect of a Strong CYP3A4 Inhibitor, Itraconazole, on the Single Dose Pharmacokinetic Profile of CTP-543 in Healthy Adult Subjects
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Deuruxolitinib (Primary)
- Indications Alopecia areata
- Focus Pharmacokinetics
- Sponsors Concert Pharmaceuticals
- 06 Apr 2021 Status changed from recruiting to completed.
- 02 Mar 2021 Status changed from not yet recruiting to recruiting.
- 09 Feb 2021 New trial record